Glioblastoma is the most prevalent and deadliest primary brain cancer , yet the treatment guidelines have not been updated in almost two decades. The typical prognosis is 15–17 months, with the tumor recurring, with a survival rate of 7–9 months. A new brain cancer vaccine called DCVax-L vaccine could increase the survival duration. In its global, phase 3 trials, the vaccine has been shown to prolong survival in newly diagnosed glioblastoma brain cancer patients by several months, with the longest survivor having lived more than eight years .
Unlike chemotherapy and radiotherapy, the majority of patients experienced no side effects. DCVax-L is a fully personalized vaccine that uses the patient's dendritic cells and tumor antigens . It takes eight days to manufacture multiple years' worth of dosages, which can be frozen, stored, and administered to the patients. The technology used to…
